-+ 0.00%
-+ 0.00%
-+ 0.00%

China Expands Reimbursement Coverage for HUTCHMED's Elunate and Orpathys

PUBT·11/16/2026 04:02:01
China Expands Reimbursement Coverage for HUTCHMED's Elunate and Orpathys
  • China's updated National Reimbursement Drug List expands coverage for HUTCHMED's Elunate and Orpathys, effective January 1, 2027.
  • Elunate gains coverage with sintilimab for eligible patients with previously treated, locally advanced or metastatic renal cell carcinoma.
  • Orpathys gains coverage with osimertinib for EGFR-mutated, MET-amplified advanced non-squamous lung cancer progressing on EGFR-targeted therapy.
  • Coverage is renewed for Orpathys in MET exon 14-skipping lung cancer; other existing indications for Elunate, Orpathys and Sulanda remain covered.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611152300PRIMZONEFULLFEED9878100) on November 16, 2026, and is solely responsible for the information contained therein.